Condition: Atrial Fibrillation (AF) · Obesity & Overweight · Sponsor: University of Eastern Finland
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
This description comes directly from the study's public registry record.
Jari Laukkanen, MD, PhD · +358505053013 · jariantero.laukkanen@uef.fi
Merja Perhonen, MD, PhD · +358406624456 · merja.perhonen@hyvaks.fi
Always discuss trial participation with your own doctor first.
| Hospital Nova of Central Finland | Jyväskylä, Central Finland, Finland | Recruiting |
| University of Eastern Finland | Kuopio, Eastern Finland, Finland | Not Yet Recruiting |
| Kuopio University Hospital | Kuopio, Northern Savonia, Finland | Not Yet Recruiting |
| Tampere University Hospital | Tampere, Finland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07430007